MA39952B1 - Programme de traitement pour composé de tiacumicin - Google Patents
Programme de traitement pour composé de tiacumicinInfo
- Publication number
- MA39952B1 MA39952B1 MA39952A MA39952A MA39952B1 MA 39952 B1 MA39952 B1 MA 39952B1 MA 39952 A MA39952 A MA 39952A MA 39952 A MA39952 A MA 39952A MA 39952 B1 MA39952 B1 MA 39952B1
- Authority
- MA
- Morocco
- Prior art keywords
- days
- tiacumicin
- clostridium difficile
- tiacumicin compound
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne un composé de tiacumicine, un stéréoisomère, un polymorphe ou un solvate pharmaceutiquement acceptable de celui-ci, et une composition pharmaceutique contenant un composé de tiacumicine, un stéréoisomère, un polymorphe ou un solvate pharmaceutiquement acceptable de celui-ci. Dans le traitement oral d'infections à clostridium difficile (cdi) ou de diarrhée ou maladie associée à clostridium difficile (cda) chez un patient conformément à un schéma posologique choisi dans le groupe comprenant: i. Administration de 200 mg du composé de tiacumicine bid pendant 5 jours suivis de 5 jours de repos, puis de 200 mg une fois par jour pendant 10 jours supplémentaires et ii. Administration de 200 mg du composé de tiacumicine bid pendant 5 jours, suivie d’une dose unique de 200 mg tous les deux jours pendant 20 jours. En outre, la présente invention concerne un procédé permettant de récupérer une population intestinale de bifidobactéries chez un patient souffrant d’infections à clostridium difficile (cdi) ou de diarrhée ou maladie associée à clostridium difficile (cd ad) et à recevoir un traitement par voie orale avec un composé de tiacumicine jusqu'à 50 à 90% des cas. La population intestinale de bifidobactéries avant l'administration du composé de tiacumicine pendant les jours 15 à 45 après le début du traitement, en administrant par voie orale le composé de tiacumicine au patient selon un schéma posologique choisi dans le groupe susmentionné.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14075031 | 2014-05-09 | ||
| EP15731245.5A EP3139932B1 (fr) | 2014-05-09 | 2015-05-11 | Programme de traitement pour composé de tiacumicin |
| PCT/EP2015/000965 WO2015169451A1 (fr) | 2014-05-09 | 2015-05-11 | Composé de tiacumicine et régime de traitement associé |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39952A MA39952A (fr) | 2017-03-15 |
| MA39952B1 true MA39952B1 (fr) | 2018-12-31 |
Family
ID=50771031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39952A MA39952B1 (fr) | 2014-05-09 | 2015-05-11 | Programme de traitement pour composé de tiacumicin |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10137141B2 (fr) |
| EP (1) | EP3139932B1 (fr) |
| JP (1) | JP6579662B2 (fr) |
| KR (1) | KR20160149288A (fr) |
| AU (1) | AU2015258130B2 (fr) |
| CA (1) | CA2948400A1 (fr) |
| CY (1) | CY1120847T1 (fr) |
| DK (1) | DK3139932T3 (fr) |
| EA (1) | EA031756B1 (fr) |
| ES (1) | ES2694028T3 (fr) |
| GE (2) | GEAP201814327A (fr) |
| HR (1) | HRP20181756T1 (fr) |
| IL (1) | IL248782B (fr) |
| LT (1) | LT3139932T (fr) |
| MA (1) | MA39952B1 (fr) |
| MD (1) | MD4695C1 (fr) |
| PL (1) | PL3139932T3 (fr) |
| PT (1) | PT3139932T (fr) |
| RS (1) | RS57994B1 (fr) |
| SI (1) | SI3139932T1 (fr) |
| TR (1) | TR201815891T4 (fr) |
| UA (1) | UA122203C2 (fr) |
| WO (1) | WO2015169451A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034885B1 (ru) * | 2015-07-03 | 2020-04-02 | Астеллас Фарма Юэроп Лтд. | Новая схема лечения тиакумициновым соединением |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4918174A (en) | 1986-09-26 | 1990-04-17 | Abbott Laboratories | Tiacumicin compounds |
| US5583115A (en) | 1995-05-09 | 1996-12-10 | Abbott Laboratories | Dialkyltiacumicin compounds |
| US5767096A (en) | 1996-07-12 | 1998-06-16 | Abbott Laboratories | Bromotiacumicin compounds |
| WO2006085838A1 (fr) | 2005-01-31 | 2006-08-17 | Optimer Pharmaceuticals, Inc. | Macrocycles a 18 chainons et leurs analogues |
| US7507564B2 (en) | 2002-07-29 | 2009-03-24 | Optimer Pharmaceuticals, Inc. | Tiacumicin production |
| ES2395404T3 (es) * | 2004-05-14 | 2013-02-12 | Optimer Pharmaceuticals, Inc. | Tratamiento de las enfermedades asociadas al uso de antibióticos |
| US7378508B2 (en) | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
| US20080176927A1 (en) * | 2007-01-19 | 2008-07-24 | Optimer Pharmaceuticals, Inc. | Compositions of stable tiacumicins |
| CN102030791B (zh) | 2010-10-28 | 2013-01-23 | 中国科学院南海海洋研究所 | 四种台勾霉素类化合物及其制备方法和在制备抗菌药物中的应用 |
| CN102115757B (zh) | 2010-12-14 | 2015-10-28 | 中国科学院南海海洋研究所 | 台勾霉素的生物合成基因簇及其应用 |
| WO2013138748A1 (fr) * | 2012-03-16 | 2013-09-19 | Optimer Pharmaceuticals, Inc. | Prévention d'infection par clostridium difficile chez des patients à haut risque |
| JO3464B1 (ar) * | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
-
2015
- 2015-05-11 WO PCT/EP2015/000965 patent/WO2015169451A1/fr not_active Ceased
- 2015-05-11 EA EA201692107A patent/EA031756B1/ru unknown
- 2015-05-11 CA CA2948400A patent/CA2948400A1/fr not_active Abandoned
- 2015-05-11 KR KR1020167034087A patent/KR20160149288A/ko not_active Ceased
- 2015-05-11 GE GEAP201814327A patent/GEAP201814327A/en unknown
- 2015-05-11 MA MA39952A patent/MA39952B1/fr unknown
- 2015-05-11 SI SI201530443T patent/SI3139932T1/sl unknown
- 2015-05-11 JP JP2016567190A patent/JP6579662B2/ja active Active
- 2015-05-11 HR HRP20181756TT patent/HRP20181756T1/hr unknown
- 2015-05-11 UA UAA201610790A patent/UA122203C2/uk unknown
- 2015-05-11 ES ES15731245.5T patent/ES2694028T3/es active Active
- 2015-05-11 RS RS20181271A patent/RS57994B1/sr unknown
- 2015-05-11 TR TR2018/15891T patent/TR201815891T4/tr unknown
- 2015-05-11 DK DK15731245.5T patent/DK3139932T3/en active
- 2015-05-11 PL PL15731245T patent/PL3139932T3/pl unknown
- 2015-05-11 EP EP15731245.5A patent/EP3139932B1/fr active Active
- 2015-05-11 US US15/309,992 patent/US10137141B2/en not_active Expired - Fee Related
- 2015-05-11 AU AU2015258130A patent/AU2015258130B2/en not_active Ceased
- 2015-05-11 LT LTEP15731245.5T patent/LT3139932T/lt unknown
- 2015-05-11 PT PT15731245T patent/PT3139932T/pt unknown
- 2015-05-11 MD MDA20160131A patent/MD4695C1/ro active IP Right Grant
- 2015-05-11 GE GEAP201514327A patent/GEP20186872B/en unknown
-
2016
- 2016-11-06 IL IL248782A patent/IL248782B/en active IP Right Grant
-
2018
- 2018-10-30 CY CY181101119T patent/CY1120847T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL248782A0 (en) | 2017-01-31 |
| WO2015169451A1 (fr) | 2015-11-12 |
| US10137141B2 (en) | 2018-11-27 |
| EA201692107A1 (ru) | 2017-04-28 |
| PT3139932T (pt) | 2018-11-14 |
| AU2015258130B2 (en) | 2019-10-31 |
| GEP20186872B (en) | 2018-06-25 |
| IL248782B (en) | 2020-08-31 |
| PL3139932T3 (pl) | 2019-02-28 |
| SI3139932T1 (sl) | 2018-12-31 |
| MD4695C1 (ro) | 2021-02-28 |
| DK3139932T3 (en) | 2018-11-12 |
| MD20160131A2 (ro) | 2017-05-31 |
| JP6579662B2 (ja) | 2019-09-25 |
| CY1120847T1 (el) | 2019-12-11 |
| UA122203C2 (uk) | 2020-10-12 |
| US20170143750A1 (en) | 2017-05-25 |
| CA2948400A1 (fr) | 2015-11-12 |
| RS57994B1 (sr) | 2019-01-31 |
| EP3139932A1 (fr) | 2017-03-15 |
| MD4695B1 (ro) | 2020-05-31 |
| HRP20181756T1 (hr) | 2018-12-28 |
| KR20160149288A (ko) | 2016-12-27 |
| EA031756B1 (ru) | 2019-02-28 |
| LT3139932T (lt) | 2018-11-12 |
| AU2015258130A1 (en) | 2016-12-15 |
| TR201815891T4 (tr) | 2018-11-21 |
| MA39952A (fr) | 2017-03-15 |
| JP2017514880A (ja) | 2017-06-08 |
| ES2694028T3 (es) | 2018-12-17 |
| GEAP201814327A (en) | 2018-02-26 |
| EP3139932B1 (fr) | 2018-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Puga et al. | Effects of drugs and excipients on hydration status | |
| MA41197B1 (fr) | Traitement de le pemphigus | |
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| Chibbar et al. | Mesalamine in the initial therapy of ulcerative colitis | |
| MA30766B1 (fr) | Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide | |
| TN2016000230A1 (en) | Orally disintegrating solid dosage unit containing an estetrol component. | |
| JP2010535767A5 (fr) | ||
| JP2019530706A5 (fr) | ||
| MA33463B1 (fr) | Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique | |
| MA50201B1 (fr) | Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants | |
| JP2018039810A5 (fr) | ||
| MA39952A (fr) | Programme de traitement pour composé de tiacumicin | |
| Chua | Metronidazole | |
| Evelo et al. | Sex differences in pharmacokinetics, pharmacodynamics, and adverse drug reactions of cardiovascular drugs | |
| Prados et al. | A population pharmacokinetic approach to describe cephalexin disposition in adult and aged dogs | |
| Kulkarni et al. | Animal models of tardive dyskinesia | |
| Chamuleau et al. | First Report on a successful screening program for MYC rearrangements and a prospective clinical trial based on MYC rearrangement in newly diagnosed DLBCL patients in the Netherlands | |
| MA49754B1 (fr) | Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag | |
| AU2018258970B2 (en) | Idalopirdine-based combinatorial therapies of Alzheimer's disease | |
| FR2899111B1 (fr) | Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament. | |
| Qu | Neurotropin/pregabalin/topiramate | |
| Mizuno | P. 3. c. 014 Antiepileptics ameliorated acute psychosis in a patient with Klinefelter's syndrome | |
| Prendecki | Cushingoid: case report | |
| Sparaco et al. | The state of liver at Chris Hani Baragwanath Hospital: 2009 | |
| Detke et al. | A phase 1b study of potential safety and pharmacokinetic interactions between cocaine and EMB-001, with exploratory efficacy measures |